Vivos Inc Expands Global Reach by Establishing Indian Subsidiary

Author: Caleb Price Updated: 09-29-2025 01:57 PM

Vivos Inc's Strategic Move into India

Vivos Inc. (OTCQB: RDGL) has received the green light from its board to set up a new corporate subsidiary in India. This crucial step signifies the company's intent to broaden its operational footprint and take part in a rapidly growing market.

Formation of Vivos Scientific India LLP

The newly authorized subsidiary will be named Vivos Scientific India LLP. The company is currently completing the necessary procedures to obtain the required formal approvals from the Indian government. This establishment aligns with Vivos Inc’s vision of fostering innovation in healthcare.

Commitment to International Business

Vivos Inc's initiative to expand into India underpins its long-term strategy of developing a global presence. By establishing this manufacturing center, Vivos aims to produce RadioGel and IsoPet products, which are pivotal for both animal treatment and human healthcare.

Developing Human Trials in India

India plays a critical role in Vivos Inc’s ongoing clinical research. The company is enthusiastic about proceeding with human trials, which began with promising results from earlier announcements made in December of the previous year. The focus is on receiving DCGI (Drug Controller General of India) approval for further human trials.

Aligning with Regulatory Standards

Vivos Inc believes that the trials in India will complement their investigational device exemption (IDE) submissions to the FDA. It’s noteworthy that the upcoming human trials will include post-treatment PET full-body scans to assess and reinforce RadioGel’s safety profile, adhering to regulatory requirements for patient safety.

Leadership Insights

According to Michael K. Korenko, Sc.D., the CEO of Vivos Inc, this move represents a significant step forward for the company's commitment to innovation and excellence in treatment technologies. The leadership is keen on advancing healthcare solutions that improve the quality of life for patients.

Connecting with Vivos Inc

For interested parties seeking more information about Vivos Inc and its innovative products, the company encourages outreach via email. You can contact CEO Michael K. Korenko at MKorenko@RadioGel.com. Keep updated through their social media presence, especially on X (Twitter) at @VivosIncUSA.

Frequently Asked Questions

What is the purpose of Vivos Inc's new subsidiary in India?

The subsidiary aims to establish a manufacturing center for RadioGel and IsoPet, supporting both animal and human health solutions.

How will Vivos Inc benefit from operating in India?

This presence in India allows Vivos to participate in emerging markets and enhance its clinical offerings through localized manufacturing and trials.

What clinical trials is Vivos Inc currently pursuing in India?

Vivos Inc is pursuing DCGI approval for human trials, aimed at assessing the safety and efficacy of their products including RadioGel.

Who is the current CEO of Vivos Inc?

The CEO of Vivos Inc is Michael K. Korenko, Sc.D., who is actively involved in the company's strategic operations.

How can one reach out to Vivos Inc for more information?

Inquiries can be made via email to Michael K. Korenko at MKorenko@RadioGel.com, or you can follow their updates on social media.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.